Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
SNDY - Solos Endoscopy NEWS!
http://www.eteligis.com/ViewSubmission.aspx?submissionRequest=28459
.
Solos Endoscopy’s MamoView(R) Demonstrates Strong Growth Potential
Nov 12, 2014 7:14:14 AM PST
BOSTON, MA, United States, 11/12/2014 - - BOSTON, MA Solos Endoscopy, Inc. (OTC Pink: SNDY) (PINKSHEETS: SNDY),a provider of quality innovative healthcare instruments to Hospitals across the Country, is pleased to announce that the company's MamoView® Breast Endoscopy System has shown strong growth over the past 18 months. Solos management has reported that MamoView(R) product sales has increased as a percentage of gross sales and in the past 18 months the company has received more than $300,000 in MamoView(R) orders from hospitals nationwide.
The Solos Endoscopy MammoView(R) Breast Endoscopy System can help give women the best prognosis for recovery by detecting breast cancer up to six times faster than conventional methods. The MammoView(R) Breast Endoscopy System allows physicians to distinguish and inspect suspicious pre-cancerous lesions undetectable by other methods.
"Management expects sales of the MamoView(R) to increase in the future as more physicians are trained in the procedure," stated Robert Segersten, President of Solos Endoscopy.
There are several teaching and research hospitals that are currently utilizing the MamoView(R) Breast Endoscopy System across the country. Management will be working with these teaching hospitals to collect data and identify new surgeons in an effort to increase sales.
Solos Endoscopy instruments are FDA approved. Solos Endoscopy intends to place the CE Mark on its entire MammoView(R) instrument line following its successful Audit with TUV America. Solos Endoscopy has posted its Certificate from TUV America on its website (http://www.solosendoscopy.com)
About Solos Endoscopy, Inc.:
Solos Endoscopy has celebrated its 25th year of providing quality innovative healthcare instruments to hospitals across the country. For more than 25 years, from medical schools to hospitals, surgeons have trusted Solos Endoscopy to develop and market breakthrough technology, applications, medical devices, and procedural techniques for the screening, diagnosis, treatment and management of disease and medical conditions. Additional information on its FDA approved products is available on the Company's website at: www.solosendoscopy.com.
Forward-Looking Statements:
Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications that may arise could prevent the prompt implementation of any strategically significant plan(s) outlined above. The company cautions that these forward-looking statements are further qualified by other factors including, but not limited to, those set forth in the company's Annual Report filing and other filings with the OTC Markets Group (available at www.otcmarkets.com). The company undertakes no obligation to publicly update or revise any statements in this release, whether as a result of new information, future events, or otherwise.
CONTACT:
Solos Endoscopy, Inc.
Investor Relations
(617) 360-9719
SOURCE: Solos Endoscopy, Inc.
http://www.eteligis.com/ViewSubmission.aspx?submissionRequest=28459
.
Solos Endoscopy’s MamoView(R) Demonstrates Strong Growth Potential
Nov 12, 2014 7:14:14 AM PST
BOSTON, MA, United States, 11/12/2014 - - BOSTON, MA Solos Endoscopy, Inc. (OTC Pink: SNDY) (PINKSHEETS: SNDY),a provider of quality innovative healthcare instruments to Hospitals across the Country, is pleased to announce that the company's MamoView® Breast Endoscopy System has shown strong growth over the past 18 months. Solos management has reported that MamoView(R) product sales has increased as a percentage of gross sales and in the past 18 months the company has received more than $300,000 in MamoView(R) orders from hospitals nationwide.
The Solos Endoscopy MammoView(R) Breast Endoscopy System can help give women the best prognosis for recovery by detecting breast cancer up to six times faster than conventional methods. The MammoView(R) Breast Endoscopy System allows physicians to distinguish and inspect suspicious pre-cancerous lesions undetectable by other methods.
"Management expects sales of the MamoView(R) to increase in the future as more physicians are trained in the procedure," stated Robert Segersten, President of Solos Endoscopy.
There are several teaching and research hospitals that are currently utilizing the MamoView(R) Breast Endoscopy System across the country. Management will be working with these teaching hospitals to collect data and identify new surgeons in an effort to increase sales.
Solos Endoscopy instruments are FDA approved. Solos Endoscopy intends to place the CE Mark on its entire MammoView(R) instrument line following its successful Audit with TUV America. Solos Endoscopy has posted its Certificate from TUV America on its website (http://www.solosendoscopy.com)
About Solos Endoscopy, Inc.:
Solos Endoscopy has celebrated its 25th year of providing quality innovative healthcare instruments to hospitals across the country. For more than 25 years, from medical schools to hospitals, surgeons have trusted Solos Endoscopy to develop and market breakthrough technology, applications, medical devices, and procedural techniques for the screening, diagnosis, treatment and management of disease and medical conditions. Additional information on its FDA approved products is available on the Company's website at: www.solosendoscopy.com.
Forward-Looking Statements:
Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications that may arise could prevent the prompt implementation of any strategically significant plan(s) outlined above. The company cautions that these forward-looking statements are further qualified by other factors including, but not limited to, those set forth in the company's Annual Report filing and other filings with the OTC Markets Group (available at www.otcmarkets.com). The company undertakes no obligation to publicly update or revise any statements in this release, whether as a result of new information, future events, or otherwise.
CONTACT:
Solos Endoscopy, Inc.
Investor Relations
(617) 360-9719
SOURCE: Solos Endoscopy, Inc.
http://www.eteligis.com/ViewSubmission.aspx?submissionRequest=28459
.
Boston shareholders were right! Sales increased as predicted. This should be just the first of a series of PR's.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=107355256
.
Stay alert! Negotiations are nearing the completion stage. Watch for news regarding Canada and possibly Europe via the Emergo Group. Financials should reflect increased sales.
One scenario would be buying coming in to burn through the .006 's and .007s and break back toward .001 before News is released. It will be one of those "somethings up" price increases you see all the time on the pinks when "insiders" start buying before anyone knows officially what's up. Then the push back through .002 after News is released, especially if the announcements and/or filings show events happening that are better than expected.
Financials due mid November for quarter ending September 30th. Look for increased sales. Other announcements regarding Canada and possible Europe through the Emergo Group out soon.
http://www.emergogroup.com
.
You must have missed this part -
However, even if the current trials are successful, the technique’s at least five years away from coming into general use.
One thing is certain, and that is if shareholders expect the dates and timelines posted in SNDY PR's, schedule's posted on their website, or President's letters to be exactly adhered to, then they will be disappointed 95% of the time. History shown that over the last 2 years, SNDY almost NEVER accomplishes anything according to timelines stated in PR's, website schedules, or President's Letters. However on the plus side, in spite of lengthy delays, they have thus far eventually accomplished everything they said they would.
Of course it doesn't say that. How could they have the Canadian License when they said they delayed the filing? You referenced the April 30th PR. The more recent announcements explain why they delayed the filing in the Presidents Letter on July 18th, and then announced they had finally filed in the October 8th PR.
The Company has delayed the filing of its application while management has been evaluating its multiple options for the Canadian market.
Solos Endoscopy has begun to expand its efforts into Canada with its filing for the Canadian Medical Device License, which will allow Solos to sell certain endoscopic instruments, including the MammoView(R) devices, in Canada.
You must have missed the July 18th Presidents letter and the October 8th PR -
http://www.otcmarkets.com/financialReportViewer?symbol=SNDY&id=123610
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=107003809
.
Thanks - Correction -Next quarterly report due mid November for quarter ending 9/30/14.
Boston alert! News imminent. Next quarterly report due mid October for quarter ending 9/30/14. Canada and Europe in play. Partnership negotiations ongoing.
SNDY Alert - Next quarterly report due out November 14th for period ending Sept. 30th. Watch for domestic sales increases and Canadian/European announcements.
The now tired and worn out R/S drum has been beating here daily now for over a year. Each time the prediction is made, it turns out to be wrong and no R/S happens. That's over a year now of failed daily R/S predictions. Throwing the same poop up at the moon daily, and hoping eventually some sticks, is not a reliable strategy.
Good to know. Thank you.
Boston says be alert! Things are happening behind the scenes with Emergo Group. Canada and Europe in play. Negotiations nearing completion.
SNDY needs to put out PR News through Marketwired to broaden the sources who publish it. IHUB carries Marketwired News among others. SNDY has not put out its last 2 PR's through Marketwired, and that is why it is not appearing on IHUB or OTCMarkets.com. Last SNDY News that was published on IHUB and OTCMarkets.com was the April 30th PR. That leaves SNDY's current expansion progress under the radar. That could be on purpose if SNDY is planning to release substantial News soon, and is waiting for certain events happening to then expand the News coverage.
http://www.marketwired.com/AdvancedSearch/AdvancedSearchResults.aspx?sid=b23ec056-481e-418c-bd60-86862035a1e6
http://www.otcmarkets.com/stock/SNDY/news
.
This News is just the beginning. Be alert for SNDY updates on Canada. Also - Emergo Group working on Europe. Sales increases in USA will be reflected in Quarter ending Sept 30th.
Be alert for SNDY updates on Canada. Also - Emergo Group working on Europe. Sales increases in USA .
If the company was diluting 60 million shares "every 2 weeks," the O/S would be more than the A/S by now, which is not the case by any means. The A/S is 2.9 Billion, and the O/S is 1.7 Billion. To say "every 2 weeks" is misleading.
That math is bogus. If it were true, there would now be 5 Billion shares in the O/S instead of 1.7 Billion. Exaggerating dilution numbers is not helpful to anyone.
Along with expansion to Canada, don't forget Europe and Emergo Group -
Looking forward in 2014, Solos Endoscopy’s ISO 13485:2003 certification will allow the company to sell the MammoView® product line in Europe and Canada. As part of the process to obtain the CE Mark, Solos Endoscopy retained Emergo Group to act as the Company's authorized representative in Europe. Emergo Group will provide Solos assistance related to communications with authorities and importation of Solos instruments into Europe.
We are pleased to inform the shareholders that we have resolved the (component manufacturer) issues and have resumed
shipping to hospitals this past week. We expect sales and cash flow to improve
over the next 90 days. In the last six months, fifteen new hospitals have begun to
carry Solos Endoscopy instruments. This includes a select number of hospitals
who are now carrying the MammoView® product line.
After the coming Canadian expansion is documented and increased sales in U.S. are reported, price increase will follow. Strategic partnership that could be the outcome of ongoing SNDY negotiations would be a game changer here. .004 short term target price depending on partnership/merger deal.
The Company is currently working
with Spectrum Medical Market Consultants to act as its representative in
Canada for its endoscopic instruments including the MammoView® devices.
Solos Endoscopy experienced significant back orders during the first six months
of 2014 due to supply issues related to a component manufacturer.
We are pleased to inform the shareholders that we have resolved the (component manufacturer) issues and have resumed
shipping to hospitals this past week. We expect sales and cash flow to improve
over the next 90 days. In the last six months, fifteen new hospitals have begun to
carry Solos Endoscopy instruments. This includes a select number of hospitals
who are now carrying the MammoView® product line.
The Company is currently working
with Spectrum Medical Market Consultants to act as its representative in
Canada for its endoscopic instruments including the MammoView® devices.
Solos Endoscopy experienced significant back orders during the first six months
of 2014 due to supply issues related to a component manufacturer.
We are pleased to inform the shareholders that we have resolved the (component manufacturer) issues and have resumed
shipping to hospitals this past week. We expect sales and cash flow to improve
over the next 90 days. In the last six months, fifteen new hospitals have begun to
carry Solos Endoscopy instruments. This includes a select number of hospitals
who are now carrying the MammoView® product line.
The company has completed everything thus far they said they would. After the coming Canadian expansion is documented, and increased sales in U.S. are reported, price increase will follow. Strategic partnership that could be the outcome of ongoing SNDY negotiations would be a game changer here.
After the coming Canadian expansion is documented and increased sales in U.S. are reported, price increase will follow. Strategic partnership that could be the outcome of ongoing SNDY negotiations would be a game changer here.
Why not? Not so long ago .004 was touted as being the absolute rock bottom price here. It was said at the time that the price would never fall below .004 so everyone should "load the boat" at .004. Of course that was said at .015 as well.
As one famous shareholder has said to his adoring minions - "Don't worry, Bob knows what he is doing."
Boston DD shows SNDY will show substantial increase in U.S. sales as well as Canadian sales channels opening up upon filing approval. Time frame - 3 to 4 weeks for final Canadian license approval. Strategic partnership negotiations ongoing for Canadian distributorship. Europe in play. Get ready for SNDY News that will jump start the coming increases in share price.
http://www.eteligis.com/ViewSubmission.aspx?submissionRequest=27796
.
SNDY short term target price .004. Boston DD shows SNDY will show substantial increase in U.S. sales as well as Canadian sales channels opening up upon filing approval. Time frame - 3 to 4 weeks for final Canadian license approval. Strategic partnership negotiations ongoing for Canadian distributorship. Europe in play. Get ready for SNDY News that will jump start the coming increases in share price.
http://www.eteligis.com/ViewSubmission.aspx?submissionRequest=27796
.
Boston DD shows SNDY ready to make the next move up in sales both domestic and foreign. Canada is happening within the next 3 weeks and Europe is next. Next financials will show marked improvement in domestic sales. Product inventories have been replenished and Canadian sales channels are being lined up and ready for final Canadian license approval.
SNDY has accomplished so far, everything they said they would. They are now set to expand to Canada and Europe. U.S sales have increased dramatically now that the delays caused by the component manufacturer have been resolved. At least 15 new hospitals added as clients here in the U.S. and sales contracts in Canada are ready and waiting for SNDY when licensing is approved in the next few weeks. Other negotiations happening as well. News coming soon.
Am I just fulfilling a wager made here, or has my own Boston DD as a result of that wager changed my mind on SNDY? The near future holds the answer to that question.
I hope you realize that we are both preaching to an empty stadium. Most longs here deserted their investment a long time ago! Very few if any participate in supporting the company or even care anymore. There is zero support here now except for me (pretty ironic) or an occasional blip from a passing demoralized long. Many who used to cheerlead have now gone negative. However if the price starts moving up, they will all come out of their hiding places and the board will explode with enthusiasm! Such is life on the stinky pinkies!
Go SNDY- BIG NEWS SOON!
Actually, sales have probably increased at least 200% in my opinion since they solved the delays that were out of their control they had in receiving component parts from the manufacturer, which had seriously hampered delivery of their products to a client list that has been steadily increasing. Adding 15 new hospitals to the list of hospitals using SNDY's endoscopy instruments has also impacted positive sales.
Wow! This is a real bombshell. The FDA is approving junk! Any company that sells junk can now get FDA approval! This is an enormous story! Any company that sells junk can get FDA approval to sell their junk, and get CE Certification on the same products to sell junk to the world! The media should be notified that all FDA approved products throughout the world should immediately be recalled because the FDA approval on those products is totally worthless because the FDA approves Junk. The FDA process is broken and worthless! This story should be taken to CNN and Fox News! We have an expert here that claims the FDA approves junk!
So you are saying that the FDA approves "junk" instruments? The 15 new hospitals that are now carrying Solos's endoscopic instruments are using FDA approved and CE Certified junk instruments on their patients?
This PR was just a followup to the President's Letter which stated they had previously delayed the application filing to consider "multiple options" the company had for expansion into Canada. This PR simply states they have filed the application. Once the application has been filed, it takes 30 days or less for the filing to be approved as per their April 30th PR. The next PR just might reveal which of those multiple options for expanding sales into Canada the company has decided to go with. One of those options could very well be a partnership or merger.
Glad you agree. SNDY has completed every step towards their goals of CE Certification and Canadian/European expansion they said they would thus far.
SNDY has completed every step towards their goals of CE Certification and Canadian/European expansion they said they would thus far. Revenue reversal is underway as we speak and the company addressed that specific subject in the last announcements, adding 15 new hospitals and solving the component part delays that had contributed to delays in sales. We still haven't heard which of the "multiple options" the company decided on for its expansion to Canada before filing for the Canadian license.